0000932471-13-003356.txt : 20130211 0000932471-13-003356.hdr.sgml : 20130211 20130211172515 ACCESSION NUMBER: 0000932471-13-003356 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20130211 DATE AS OF CHANGE: 20130211 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: KALOBIOS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001293310 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770557236 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-87188 FILM NUMBER: 13593354 BUSINESS ADDRESS: STREET 1: 260 EAST GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.243.3100 MAIL ADDRESS: STREET 1: 260 EAST GRAND AVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: VANGUARD GROUP INC CENTRAL INDEX KEY: 0000102909 IRS NUMBER: 231945930 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: PO BOX 2600 STREET 2: V26 CITY: VALLEY FORGE STATE: PA ZIP: 19482-2600 BUSINESS PHONE: 6106691000 MAIL ADDRESS: STREET 1: PO BOX 2600 STREET 2: V26 CITY: VALLEY FORGE STATE: PA ZIP: 19482-2600 SC 13G 1 kalobiospharmaceuticals.htm kalobiospharmaceuticals.htm - Generated by SEC Publisher for SEC Filing

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Schedule 13G

 

Under the Securities Exchange Act of 1934

(Amendment No.:0)*

 

 

 

Name of issuer:  KaloBios Pharmaceuticals Inc

 

 

Title of Class of Securities:  Common Stock

 

 

CUSIP Number:  48344T100

 

 

Date of Event Which Requires Filing of this Statement:  January 31, 2013

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

  (X) Rule 13d-1(b)

  (  ) Rule 13d-1(c)

  (  ) Rule 13d-1(d)

 

  *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

  The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

(Continued on the following page(s))

 

 


 

 

13G

CUSIP No.:  48344T100

 

 

1.  NAME OF REPORTING PERSON

  S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 

  Vanguard Investment Series PLC – U.S. Opportunities Fund

 

2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

 

A.

B.

 

3.  SEC USE ONLY

 

 

 

4.  CITIZENSHIP OF PLACE OF ORGANIZATION

 

  Ireland

 

(For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

 

5.  SOLE VOTING POWER

 

  2,486,375

 

6.  SHARED VOTING POWER

 

     

 

7.  SOLE DISPOSITIVE POWER

 

0

 

8.  SHARED DISPOSITIVE POWER

 

0

 

 

9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  2,486,375

 

10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

  N/A

 

11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  10.30%

 

12.  TYPE OF REPORTING PERSON

 

  FI

 


 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

Under the Securities Act of 1934

 

Check the following [line] if a fee is being paid with this statement   N/A

 

Item 1(a) - Name of Issuer:

 

  KaloBios Pharmaceuticals Inc

 

 

Item 1(b) - Address of Issuer's Principal Executive Offices:

 

  260 East Grant Ave

  South San Francisco, CA 94080

 

Item 2(a) - Name of Person Filing:

 

  Vanguard Investment Series PLC - U.S. Opportunities Fund

 

Item 2(b) – Address of Principal Business Office or, if none, residence:

 

  100 Vanguard Blvd.

  Malvern, PA  19355

 

Item 2(c) – Citizenship:

 

  Ireland

 

Item 2(d) - Title of Class of Securities:

 

  Common Stock

 

Item 2(e) - CUSIP Number

 

  48344T100

 

Item 3 - Type of Filing:

 

  This statement is being filed pursuant to Rule 13d-1.  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).

 

Item 4 - Ownership:

 

  (a) Amount Beneficially Owned:

 

  2,486,375

 

  (b) Percent of Class:

 

  10.30%

 


 

 

  (c)  Number of shares as to which such person has:

 

  (i)  sole power to vote or direct to vote:  2,486,375

 

  (ii)  shared power to vote or direct to vote:     

 

  (iii)  sole power to dispose of or to direct the disposition of:  

 

  (iv)  shared power to dispose or to direct the disposition of:  

 

Comments:

 

 

Item 5 - Ownership of Five Percent or Less of a Class:

 

  Not Applicable

 

Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

 

  Not applicable

 

Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company

 

  Not Applicable

 

Item 8 - Identification and Classification of Members of Group:

 

  Not applicable

 

Item 9 - Notice of Dissolution of Group:

 

  Not applicable

 

Item 10 - Certification:

 

  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

 

Signature

 

  After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

Date:  02/11/2013

 

By /s/ Michael S. MIller  

 

Michael S. Miller

 

Director